Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study
The EU regulator, according to an EMA document, said it revoked Amgen’s Tavneos marketing authorization after finding “serious breaches” in the drug’s pivotal trial, including access to unblinded efficacy data and rerunning primary analysis that changed results. The EU concluded the study was unreliable. Tavneos is also under FDA scrutiny; Amgen requested a hearing.
How this was made
The 30-second read
Why it matters
The EMA’s reasoning centers on study integrity breaches: unblinded efficacy visibility after database lock, undisclosed re-adjudication, and a rerun that changed the primary endpoint from non-significant to significant. The regulator concluded the overall study was unreliable and the risk-benefit profile could not be made positive.
Market read
A regulator’s detailed revocation rationale is a fresh, decision-grade catalyst that increases downside risk for Amgen’s Tavneos franchise and raises the probability of adverse FDA outcomes or further market actions.
What to watch
The article does not quantify Tavneos revenue exposure, and the FDA outcome could diverge from the EU’s conclusions depending on how the agency weighs the rerun and disclosure issues.
Background
Tavneos (ANCA-associated vasculitis) was approved in 2021; EU regulators revoked its marketing authorization last week, and this article adds the EMA’s detailed rationale.
Ticker impact
EU regulators revoked Tavneos’ marketing authorization, citing “serious breaches” including unblinding and rerunning primary analysis without regulator disclosure.
Bearish bias with elevated volatility; downside risk likely outweighs upside until FDA process clarifies.
The article describes a concrete EU revocation decision tied to study integrity, plus ongoing FDA scrutiny and Amgen’s hearing request with a new data package.
Market effects
Raises scrutiny risk for biotech clinical-trial integrity and could pressure valuation multiples for similar rare-disease programs in Europe.
EU regulatory actions reinforce a tougher stance on trial conduct, potentially affecting European biotech sentiment.
EU findings strengthen the evidentiary backdrop for FDA review and any future enforcement or re-adjudication disputes.
Counterpoint
Amgen is contesting the FDA allegations with a new analysis package and patient testimony, which could limit incremental damage if FDA accepts the revised evidence.
Key entities
- companyAmgen
Subject of the article; EU revocation of Tavneos and ongoing FDA scrutiny.
- drugTavneos
Amgen rare-disease drug whose EU marketing authorization was revoked over pivotal trial integrity issues.
- regulatorEuropean Medicines Agency (EMA)
Released the reasoning citing serious breaches in clinical trial guidelines and study unreliability.
- companyCSL Vifor
Owns marketing rights to Tavneos in the region, referenced in the article’s context of the EU decision.
- companyChemoCentryx
Developed Tavneos before being acquired by Amgen in 2022; study personnel are implicated in the EMA’s described unblinding and rerun process.
